小脑后下动脉动脉瘤的诊断和治疗

目的探讨小脑后下动脉动脉瘤的临床特征、诊断、鉴别诊断和治疗。方法回顾性分析12例小脑后下动脉瘤的临床表现、影像学特征、手术效果及诊治过程中存在的相关问题。结果12例中有11例因动脉瘤破裂出血而发病,单纯第四脑室出血4例,全脑室系统出血2例,小脑半球出血3例,小脑蚓部伴第四脑室出血1例,侧脑室伴第三脑室出血1例,以后颅窝占位病变表现1例。8例术前行DSA检查明确诊断,4例术中明确诊断。12例均行后颅窝开颅显微手术治疗,其中动脉瘤颈夹闭9例,孤立切除2例,动脉瘤加固术1例,术后2例因脑积水加重行脑室-腹腔分流术。12例中除1例术后留有轻偏瘫外,其余11例恢复良好。结论小脑后下动脉瘤多以第四脑室出血发病,少数以小脑半球或蚓部出血发病,及早治疗效果满意。手术方式应尽量夹闭动脉瘤颈,对于小脑后下动脉末端动脉瘤,可以采用孤立切除术。     

眶内眼动脉瘤合并脑海绵状血管畸形一例并文献复习

目的探讨眶内眼动脉瘤合并连续出血的脑海绵状血管畸形的临床表现特点和诊治要领。方法报告1例眶内眼动脉瘤并发反复出血的脑海绵状血管畸形患者临床资料,并复习相关文献。结果该患者先行脑海绵状血管畸形切除,分期手术作眶内眼动脉瘤夹闭,治疗结果良好。结论眶内眼动脉瘤极其罕见,应个体化制定治疗方案;手术夹闭动脉瘤颈是眶内眼动脉瘤的首选治疗方法。     

股前外侧区穿支动脉的形态学研究及皮瓣设计

目的探讨以旋股外侧动脉降支为蒂的皮瓣设计方法，以便增加术前多普勒定位的准确性。方法6具动脉灌注明胶-氧化铅混悬液的新鲜成人整尸标本，解剖观测股前外侧区穿支，通过血管造影术和拍摄X线片测量其直径、行程、分支和定位。用3D—doctor和Scion Image软件分别测量穿支供血的趋向性、三维重建和单穿支供血面积。结果股前外侧区共有外径大于0．5mm穿支16支，平均外径0．8mm，平均供血面积45．61cm^2，其中20％为肌间隙穿支，80％为肌皮穿支。平均蒂长为（3．15±1．43）cm。自旋股外侧动脉降支发出的穿支在浅筋膜中的平均长度为2．63cm。结论改良的氧化铅-明胶灌注技术可以为皮动脉和穿支皮瓣的研究提供高质量的血管造影图像。本研究发现股前外侧单穿支皮瓣的最大供血面积是30cm×20cm。以股前外侧区穿支设计的穿支皮瓣可以移植到下肢或身体其他部位。     

腹腔镜治疗精索静脉曲张235例

目的探讨腹腔镜治疗精索静脉曲张的疗效. 方法回顾分析1993年9月～2003年7月235例经腹腔镜精索静脉高位结扎术的临床资料. 结果 235例手术均获成功,手术时间5～20 min,平均12 min.术后住院2～5 d,平均3 d.210例随访6～18个月,9例复发,复发率4.3%(9/210),不育11例术后6～12个月后其妻受孕. 结论腹腔镜精索静脉高位结扎术微创、美观、疗效好,对双侧精索静脉曲张、开放性手术后复发和有腹股沟区手术史者尤为适用.     

冠心病患者CRP水平与肾动脉狭窄的关系

【论文特点介绍】本研究观察了CRP是否可以作为肾动脉粥样硬化狭窄（ARAs）的独立危险因子。通过对危险因素进行多变量Logistic回归分析，结果表明年龄、冠脉病变严重程度、外周血管疾病是ARAS的独立危险因素，而CRP水平、高血压、高脂血症、肾功能不全并非ARAS的独立危险因素。     

CT血管成像对肝细胞癌合并肝动脉-门静脉分流的诊断价值

目的探讨CT血管成像（CTA）对肝细胞癌（HCC）合并肝动脉-门静脉分流（APS）的诊断价值。方法127例HCC患者分别接受肝脏多层螺旋CT动态增强扫描和DSA检查，间隔时间3-15d。所有患者进行CTA检查，并以DSA为标准，对照分析CT动态增强扫描基础上进行CTA成像对APS的诊断价值。结果DSA证实52例（40．94％）HCC患者合并APS，中央型33例，周围型19例。CT横断面与横断面基础上结合CTA诊断APS的敏感度均为94．23％（49／52），特异度分别为84．00％（63／75）和97．33％（73／75），正确率分别为88．19％（112／127）和96．06％（122／127），阳性预测值分别为80．33％（49／61）和96．08％（49／51），阴性预测值分别为95．45％（63／66）和96．05％（73／76）。CTA排除了横断面CT对4例中央型APS和6例周围型APS的假阳性诊断。与DSA比较，多层螺旋CT对APS的分型符合率达88．46％（46／52），其中，中央型90．91％（30／33），周围型84．21％（16／19）。CTA还直观地显示23例重度分流中央型APS的供血动脉，其中19例为肝固有动脉分支，4例为胃十二指肠动脉分支。结论在多层螺旋CT动态增强扫描基础上进行CTA成像，能有效提高APS诊断的特异度和正确率。     

Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients

Background and aims Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We report our experience in the use of RFA for the management of unresectable hepatic malignancies. Patients and methods Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%). All patients were followed to assess complications, treatment response and recurrence of malignant disease. Results Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression (17%), 21 patients (23,9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound. Thirty-six patients received simultaneous resection and RFA. Conclusion RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.     

The carotid endarterectomy: Experience with 260 cases and discussion of the indications

Summary During 1978 to 1989, 235 patients were operated upon with 260 procedures for cervical carotid endarterectomy. The patients were classified according to the presence or absence of ischaemic symptomatology, and for symptomatic patients, according to the reversibility or persistance of ischaemic symptoms. So the selection of patients was: reversible ischaemia 46%, stroke 29%, asymptomatic patients 25%. In the stroke group, no patient was operated on as an emergency, the endarterectomy was only performed after stabilization of the clinical state. Three subgroups were included in patients operated on for asymptomatic carotid stenosis: casual discovery 40%, treatment of the second carotid artery (previous endarterectomy for symptomatic contralateral stenosis) 34%, and treatment of the second carotid artery (previous ECIC by-pass for contralateral carotid occlusion) 26%. All patients were operated upon after angiographic exploration (femoral catheterisation in most cases), and after cerebral CT scan. The surgical technique included general anaesthesia, systematic shunting, endarterectomy after longitudinal arteriotomy, closure without patch. The operating microscope has been used since 1985.The surgical results were studied in terms of uneventful postoperative course (87%), reversible complications (8%) and long lasting complications (5%). The long lasting complications were of local origin (1%), of neurological origin (2%), of general origin (1%). Overall the operative outcome at 6 months was: return to previous clinical state 95%, neurological sequelae 2%, death 3%. In the patients operated on for asymptomatic carotid stenosis the overall outcome was: previous clinical state 97%, death 3%. The legitimacy of carotid endarterectomy procedure is discussed in relation to some recent pertinent literature.     

选择髂内或髂外动脉吻合对移植肾的影响

目的 探讨肾移植动脉重建选择髂外或髂内动脉时移植肾血流参数、肾脏功能和血管并发症的差异。方法 135例初次肾移植患者随机分为2组，2组患者平均年龄、HLA错配数目、淋巴细胞毒试验、冷／热缺血时间差异均无统计学意义（P〉0．05），术后免疫抑制剂应用方案相同。应用髂外动脉端侧吻合66例，髂内动脉端端吻合69例。随访3个月，比较2组患者肾脏功能、彩色多普勒肾脏血流参数和血管并发症发生率。结果 髂内动脉、髂外动脉组2组患者术后3个月时肾功能监测指标（Cr：118．41 vs123．68μmol／L），移植肾主肾动脉、段动脉、大叶间动脉血流及阻力指数差异无统计学意义（P〉0．05）。结论 肾移植动脉重建选择髂内外动脉对移植肾功能及血液流变学无明显影响，动脉选择应根据患者具体情况决定。     

羟乙基淀粉130/0.4对非体外循环冠状动脉搭桥术患者凝血功能的影响

目的比较非体外循环冠状动脉搭桥术(0PCAB)中临床剂量的羟乙基淀粉(HES)130／0．4和琥珀酰明胶对凝血功能的影响。方法选择24例美国麻醉医师协会(ASA)分级Ⅱ～Ⅲ级、择期行OPCAB的患者,随机均分为琥珀酰明胶组(GEL组)和HES组。分别于麻醉诱导前(T0)、术毕即时(T1)和术后24 h(T2)测定血小板计数、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(Fib)和D-二聚体等凝血功能指标。记录术中失血量、术后24 h内的胸管引流量和输血量。结果两组间手术时间、术中补液量、术中出血量和24 h胸管引流量的差异均无显著性(P值均>0．05)。两组间T0、T1和T2时间点的血小板计数、PT、APTT、Fib及D-二聚体的差异均无显著性(P值均>0．05)。结论临床剂量的HES 130／0．4与琥珀酰明胶对OPCAB患者凝血功能的影响无明显差异,可安全应用于OPCAB的容量治疗。